Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
Butler J, Filippatos G, Siddiqi TJ, Ferreira JP, Brueckmann M, Bocchi E, Böhm M, Chopra VK, Giannetti N, Iwata T, Januzzi JL, Kaul S, Piña IL, Ponikowski P, Rauch-Kröhnert U, Shah SJ, Senni M, Sumin M, Verma S, Zhang J, Pocock SJ, Zannad F, Packer M, Anker SD. Butler J, et al. Among authors: pocock sj. Circulation. 2022 Oct 4;146(14):1046-1055. doi: 10.1161/CIRCULATIONAHA.122.059755. Epub 2022 Sep 13. Circulation. 2022. PMID: 36098051 Free PMC article. Clinical Trial.
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.
Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Solomon SD, et al. Circulation. 2005 Dec 13;112(24):3738-44. doi: 10.1161/CIRCULATIONAHA.105.561423. Epub 2005 Dec 5. Circulation. 2005. PMID: 16330684 Clinical Trial.
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Hillege HL, et al. Circulation. 2006 Feb 7;113(5):671-8. doi: 10.1161/CIRCULATIONAHA.105.580506. Circulation. 2006. PMID: 16461840
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA; CHARM Committees and Investigators. O'Meara E, et al. Circulation. 2006 Feb 21;113(7):986-94. doi: 10.1161/CIRCULATIONAHA.105.582577. Epub 2006 Feb 13. Circulation. 2006. PMID: 16476847
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Piña IL, Granger CB, Ostergren J, Michelson EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators. O'Meara E, et al. Circulation. 2007 Jun 19;115(24):3111-20. doi: 10.1161/CIRCULATIONAHA.106.673442. Epub 2007 Jun 11. Circulation. 2007. PMID: 17562950 Clinical Trial.
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, Pfeffer MA, Yusuf S, Swedberg K, Michelson EL, Granger CB, McMurray JJ, Solomon SD; CHARM Investigators. Kenchaiah S, et al. Among authors: pocock sj. Circulation. 2007 Aug 7;116(6):627-36. doi: 10.1161/CIRCULATIONAHA.106.679779. Epub 2007 Jul 16. Circulation. 2007. PMID: 17638930 Clinical Trial.
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Solomon SD, et al. Circulation. 2007 Sep 25;116(13):1482-7. doi: 10.1161/CIRCULATIONAHA.107.696906. Epub 2007 Aug 27. Circulation. 2007. PMID: 17724259
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Pocock SJ, McMurray JJ, Dobson J, Yusuf S, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon SD, Anker SD, Swedberg KB. Pocock SJ, et al. Eur Heart J. 2008 Nov;29(21):2641-50. doi: 10.1093/eurheartj/ehn420. Epub 2008 Sep 26. Eur Heart J. 2008. PMID: 18819960 Clinical Trial.
566 results